Low-dose naltrexone for post-COVID fatigue: randomized preprint
Naik H et al. · 2026 · medRxiv preprint
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind 16-week trial of oral low-dose naltrexone titrated from 1 mg up to 4.5 mg daily or placebo. Primary outcome was the Fatigue Severity Scale.
Dose, route and schedule
Double-blind 16-week trial of oral low-dose naltrexone titrated from 1 mg up to 4.5 mg daily or placebo. Primary outcome was the Fatigue Severity Scale.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Fatigue at week 16 | Week 16 mean fatigue scores were 4.2 with naltrexone and 4.4 with placebo. The adjusted total-score difference was −0.76 (95% CI −4.18 to 2.67). | |
| Secondary measures | The authors found no significant benefit on pain, symptom score, steps or quality of life. |
Preprint, pending peer review. Post-COVID fatigue syndrome is the enrolled population.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Preprint, pending peer review. Post-COVID fatigue syndrome is the enrolled population.
Related publications may cover the same research program or participants.
Source access
Double-blind 16-week trial of oral low-dose naltrexone titrated from 1 mg up to 4.5 mg daily or placebo. Primary outcome was the Fatigue Severity Scale.
Source reviewed 2026-11-12.
Citation and original source
Original source: Naik H et al.. Low-dose naltrexone for post-COVID fatigue: randomized preprint medRxiv preprint 2026.
Molekul research summary: https://molekul.io/research/naltrexone-post-covid-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry